Fundraising FoxOxford Bioscience Partners
Find your way into Oxford Bioscience Partners
Sign up to see every warm intro you have to Oxford Bioscience Partners
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oxford Bioscience Partners team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
What they invest in
from 5 of 5 portfolio companiesBiotech ×4Healthtech ×4Medical Devices ×2Digital Health ×1Hardware ×1
HQs:United States×4
Investments · 5 tracked
founders shown can be your intro pathBiotechFramingham, US
Woojin Lee(Executive Officer, Director)inJohn Schulte(Executive Officer, Director)
BoardGlen Kashuba(Director)inHoward Donnelly(Director)Jeff Barnes(Director)
Co-investorsBoston Harbor Angels
CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control.
BiotechHealthtechMedical DevicesMarlborough, US
Lauren Jennings(Executive Officer)Warren Clark(Executive Officer)Stephen Sagon(Executive Officer, Director)inAnjie Roldan(Executive Officer)inWarren R. Clark III(Executive Officer)Stephan S. Ogilvie(CEO)in
Co-investorsBioBritSaints CapitalSV Health InvestorsAccuitive Medical VenturesSV Life Sciences
A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.
BiotechDigital HealthHealthtech
Co-investorsAccess BiotechnologyBain Capital Life SciencesRidgeback CapitalRA Capital
HydroCision develops minimally invasive surgical instruments using proprietary FluidJet technology to selectively remove soft tissue in a precise manner.
BiotechHardwareHealthtechMedical DevicesNorth Billerica, US
PAUL KOWALSKI(Executive Officer)inRICHARD A. LYTLE, III(Executive Officer, Director)THOMAS D. ABERT(Executive Officer)inPATRICIA VANBLARCOM(Executive Officer)Rick Lytle(President & Chief Executive Officer)in
BoardLONG ZHAN(Director)
Co-investorsBioVenturesNewbury Ventures
HealthtechTewksbury, US
Lisa Mastromattei(Executive Officer)Lisa Wipperman Heine(Executive Officer)Sophia Wong(Executive Officer)Richard P. Geoffrion(Executive Officer, Director)
BoardMartien Van Osch(Director)Daniel Cole(Director)
Co-investors415 CapitalQiming Venture PartnersSaints CapitalXeraya CapitalForbion
Fund performance · per public LP disclosures · 4
as of Jun 2020| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Oxford Bioscience Partners IVLPs: The Regents of the University of California | 2001 | — | -6.6% | 0.71x | 0.71x |
| Oxford Bioscience Partners IV, L.PLPs: The Regents of the University of California | 2001 | — | -6.6% | 0.71x | 0.71x |
| Oxford Bioscience Partners IIILPs: The Regents of the University of California | 1999 | — | -13.4% | 0.38x | 0.38x |
| Oxford Bioscience Partners III, L.PLPs: The Regents of the University of California | 1999 | — | -13.4% | 0.38x | 0.38x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has Oxford Bioscience Partners made?
- Oxford Bioscience Partners has 5 tracked investments.